Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

NCT01682213 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Dabrafenib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]